Zai Lab Ltd
$ 21.96
2.91%
14 Apr - close price
- Market Cap 2,335,556,000 USD
- Current Price $ 21.96
- High / Low $ 22.45 / 21.68
- Stock P/E N/A
- Book Value 6.47
- EPS -1.60
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.23 %
- 52 Week High 44.34
- 52 Week Low 15.96
About
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
Analyst Target Price
$37.31
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-07 | 2023-05-09 |
| Reported EPS | -0.46 | -0.33 | -0.37 | -0.45 | -0.8 | -0.42 | -0.8 | -0.5 | -1 | -0.71 | -1.25 | -0.51 |
| Estimated EPS | -0.3712 | -0.25 | -0.41 | -0.5475 | -0.6333 | -0.78 | -0.71 | -0.92 | -0.86 | -1.04 | -0.79 | -0.95 |
| Surprise | -0.0888 | -0.08 | 0.04 | 0.0975 | -0.1667 | 0.36 | -0.09 | 0.42 | -0.14 | 0.33 | -0.46 | 0.44 |
| Surprise Percentage | -23.9224% | -32% | 9.7561% | 17.8082% | -26.3224% | 46.1538% | -12.6761% | 45.6522% | -16.2791% | 31.7308% | -58.2278% | 46.3158% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.58 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZLAB
2026-04-13 21:09:19
This article examines Zai Lab Ltd (ZLAB), a Cayman Islands-incorporated biotech company listed on Nasdaq, focusing on its role for U.S. investors seeking exposure to China’s biotech market. Zai Lab operates through an asset-light model, in-licensing late-stage therapies for the Greater China market, primarily in oncology and immunology. The report discusses the company's business model, competitive advantages, future growth drivers, and risks associated with U.S.-China trade tensions and regulatory environments, offering insights for diversified portfolios.
2026-04-13 03:40:45
Zai Lab (ZLAB) is gaining attention due to progress in its Phase 3 DLLEVATE trial for small cell lung cancer and a new collaboration with Amgen. Despite a recent share price rebound, analysts suggest the stock is 58.2% undervalued with a fair value of $49.49, anticipating significant revenue growth and a shift to profitability. However, potential risks include competition and pricing pressures in China.
2026-04-08 23:09:50
Zai Lab's CFO, Yajing Chen, sold 853 American Depositary Shares (ADSs) on April 6, 2026, at an average price of $20.448 per ADS. This sale was automatically executed to cover taxes associated with the vesting of Restricted Share Units, indicating it was a tax-withholding transaction rather than a discretionary divestment. After the sale, Chen still directly holds 31,705 ADSs.
2026-04-08 23:09:50
Zai Lab Ltd officer Joshua L. Smiley automatically sold 3,017 American Depositary Shares (ADSs) on April 6, 2026, at $20.448 per ADS to cover tax obligations arising from the vesting of Restricted Share Units. After this transaction, Smiley still directly holds 117,602 ADSs, maintaining a significant equity position in the company. Each ADS represents ten Ordinary Shares of Zai Lab.
2026-04-08 23:09:50
Zai Lab Ltd executive Rafael Amado sold 2,739 American Depositary Shares (ADSs) at a price of $20.448 per ADS. This sale was not a discretionary transaction but rather an automatic sale executed to cover tax obligations incurred upon the vesting of Restricted Share Units. Following this transaction, Amado directly holds 57,022 ADSs, with each ADS representing ten ordinary shares.
2026-04-08 23:09:50
Zai Lab Ltd's Chief Legal Officer, Edmondson Frazor Titus III, automatically sold 1,224 American Depositary Shares (ADSs) to cover taxes associated with the vesting of Restricted Share Units (RSUs) on April 6, 2026. The ADSs were sold at an average price of $20.448 per ADS. Following this transaction, Edmondson Frazor Titus III directly holds 23,366 ADSs, with each ADS representing ten Ordinary Shares.
